DR6 as a diagnostic and predictive biomarker in adult sarcoma.

PloS One
Kun YangRonald J Buckanovich

Abstract

The Death Receptor 6 (DR6) protein is elevated in the serum of ovarian cancer patients. We tested DR6 serum protein levels as a diagnostic/predictive biomarker in several epithelial tumors and sarcomas. DR6 gene expression profiles were screened in publically available arrays of solid tumors. A quantitative immunofluorescent western blot analysis was developed to test the serum of healthy controls and patients with sarcoma, uterine carcinosarcoma, bladder, liver, and pancreatic carcinomas. Change in DR6 serum levels was used to assay the ability of DR6 to predict the response to therapy of sarcoma patients. DR6 mRNA is highly expressed in all tumor types assayed. Western blot analysis of serum DR6 protein demonstrated high reproducibility (r = 0.97). Compared to healthy donor controls, DR6 serum levels were not elevated in patients with uterine carcinosarcoma, bladder, liver, or pancreatic cancers. Serum DR6 protein levels from adult sarcoma patients were significantly elevated (p<0.001). This was most evident for patients with synovial sarcoma. Change in serum DR6 levels during therapy correlated with clinical benefit from therapy (sensitivity 75%, and positive predictive value 87%). DR6 may be a clinically useful diagnostic a...Continue Reading

References

Jan 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C L LoprinziA Y Chang
Aug 4, 1998·European Journal of Biochemistry·K Schulze-OsthoffM E Peter
Oct 31, 2002·American Journal of Medical Genetics·Avery A Sandberg
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil H SegalAlan N Houghton
May 1, 2004·Proceedings of the National Academy of Sciences of the United States of America·Eric M TamChristopher M Overall
Aug 16, 2005·The Medical Journal of Australia·Peter T Nash, Timothy H J Florin
Jan 6, 2006·Current Directions in Autoimmunity·Hui-Chen HsuJohn D Mountz
Apr 15, 2006·The Oncologist·Remco van HorssenAlexander M M Eggermont
Jun 17, 2006·Breast Cancer Research : BCR·Bernard TêtuDominique Trudel
Mar 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald J BuckanovichGeorge Coukos
Sep 18, 2009·Advances in Experimental Medicine and Biology·Robert BenschopSongqing Na
Mar 4, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey WiezorekJonathan Graves
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Zoya YurkovetskyAnna E Lokshin
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward
Oct 16, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roy S HerbstPatricia M LoRusso
Nov 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Hai Minh TaKyeong Kyu Kim
Aug 11, 2015·Frontiers in Immunology·Sandip Sonar, Girdhari Lal

❮ Previous
Next ❯

Citations

Aug 13, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Peter UrbanMaria Marekova
Apr 4, 2014·Disease Markers·Miroslava Bilecova-RabajdovaMaria Marekova

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
Infrared Imaging
ELISA

Software Mentioned

GraphPad Prism5
LI
XL
SAS
COR Odyssey

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Carcinosarcoma

Carcinosarcoma is a malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. Discover the latest research on carcinosarcoma here.